Ensysce Biosciences selects PF9001 to move into IND-enabling studies

Ensysce Biosciences announced the achievement of a critical milestone in its opioid use disorder program with the selection of a lead drug candidate to move into Investigational New Drug enabling studies. Designed with the application of Ensysce’s TAAP platform to reduce the abuse profile, lead candidate PF9001 has shown lower potential for cardiovascular side effects associated with traditional methadone opioid use disorder treatments. This work has been supported by a multi-year Helping to End Addiction Long-Term award of up to $15 million granted by the NIH and National Institute on Drug Abuse.